1. Introduction
===============

Perimesencephalic nonaneurysmal subarachnoid hemorrhage (PNSAH), identified by van Gijn et al. in 1985,^\[[@R1]\]^ has been well recognized as a distinct clinical and imaging entity that contributes approximately 8% to 11% of the patients with subarachnoid hemorrhage (SAH) and constitutes 21% to 68% of those with a negative angiogram.^\[[@R2]\]^ Radiographically, PNSAH is characterized by normal 4-vessel angiography in combination with a pattern of extravasated blood restricted to the perimesencephalic cisterns or prepontine cisterns, without the extension of blood to lateral Sylvian fissures, anterior interhemispheric fissures, and lateral ventricles on computed tomographic imaging.^\[[@R3]\]^ In contradistinction to aneurysmal SAH, PNSAH has an excellent prognosis with an uneventful clinical course and a low risk of vasospasm, rebleeding, hydrocephalus, and delayed cerebral ischemia.^\[[@R4],[@R5]\]^ However, many patients with PNSAH complained of functional decline which prevented them from returning to work.^\[[@R6]\]^ The pathogenesis and mechanisms of the PNSAH are controversial. Theories include rupture of perforating arteries or capillary, basilar artery dissection, thrombosed arterial aneurysms, cavernous malformations, and dural arteriovenous fistula.^\[[@R7]\]^ Recently, several studies have reported an association between intracranial venous hypertension and PNSAH.^\[[@R7]--[@R11]\]^ This presumption is supported by reports on PNSAH induced by straining and physical exertion,^\[[@R11]\]^ as well as more recent studies highlighting abnormal venous drainage patterns of the basal vein of Rosenthal.^\[[@R7],[@R12]--[@R14]\]^ The presence of underlying anomaly in cerebral venous circulation, such as stenosis of straight sinus,^\[[@R9]\]^ jugular vein,^\[[@R8]\]^ and vein of Galen,^\[[@R12],[@R15],[@R16]\]^ has been implicated in several case reports as an important predisposing factor in the pathogenesis of PNSAH.^\[[@R9],[@R15]--[@R17]\]^

Herein, we described a case of rarely reported transverse sinus thrombosis producing intracranial venous hypertension and the occurrence of PNSAH. It provided strong support to the hypothesis that the source of PNSAH is venous in origin.^\[[@R7]\]^ Then, a review of published literature was undertaken to reveal the association between underlying venous pathology and PNSAH.

2. Consent
==========

Written informed consent was obtained from the patient before and after all procedures.

3. Case report
==============

A 45-year-old right-handed Chinese man presented to our hospital with a 6-hour history of sudden onset of a severe headache in the occipital-temporal orientation, associated with nausea, vomiting, and mild photophobia. The headache was persistent and unresponsive to non-steroid analgesics. He had no relevant family history of thrombosis or hemorrhage. His past medical history was unremarkable without risk factors such as diabetes, hypertension, hypercholesteremia, autoimmune disorders, alcohol consumption, cigarette smoking, or drug abuse. Upon arrival to the emergency department, the patient was fully conscious and totally alert, presenting apparently a normal higher cortical function, but suffering from severe headache, photophobia, stiff neck and vomiting with a Glasgow Coma Scale of 15/15. The severity of SAH was assessed as grade 2 on the Hunt & Hess scale and grade 1 on World Federation of Neurological Surgeons (WFNS) scale. No abnormalities or focal neurologic deficits were remarkable except for stiff neck in a general physical examination.

An emergency noncontrast brain computed tomography (CT) revealed an acute subarachnoid hemorrhage restricted to the perimesencephalic and prepontine cisterns. There was no extension of the hemorrhage to interhemispheric fissure and the Sylvian fissures. This pattern of hemorrhage was well known as a perimesencephalic SAH (Fig. [1](#F1){ref-type="fig"}A--C). Followed CT angiography did not reveal any evidence of an intracranial aneurysm or underlying vascular malformation. The patient was admitted to the neurology intensive care unit for making preparations for digital subtraction angiography (DSA). On the second day after hospitalization, DSA showed no evidence of an aneurysm and vascular malformation in arterial and capillary phases (Fig. [2](#F2){ref-type="fig"}A and B). Assessment of the venous phase of left internal carotid artery angiogram showed normal cortical veins, superior sagittal sinus, and left transverse sinus (Fig. [2](#F2){ref-type="fig"}D and F). But the assessment of the venous phase of right internal carotid artery angiogram demonstrated an absence of normal venous outflow of the right transverse sinus and prominent cerebral veins as extensive collateralizations (Fig. [2](#F2){ref-type="fig"}C and E). The findings suggested right transverse sinus thrombosis. Brain magnetic resonance images were conducted to confirm the diagnosis of cerebral sinus thrombosis 3 days after admission, which revealed an image of normal gray and white matter, without lesions in the brain parenchyma. However, the images of the right transverse sinus revealed the presence of a hyperintense lesion on both T1-weighted image and T2-weighted image inside the sinus (Fig. [3](#F3){ref-type="fig"}A--C), suggestive of the replacement of signal void by thrombus. Axial gadolinium-enhanced T1-weighted images demonstrated filling defects in the right transverse sinus and sigmoid sinus (Fig. [3](#F3){ref-type="fig"}D), compatible with the absence of flow on contrast MR venography (Fig. [3](#F3){ref-type="fig"}E and F).

![Axial sections of noncontrast brain computed tomographic imaging at symptom onset demonstrated acute hemorrhage (yellow arrow) localized in the left perimesencephalic cistern (A) and prepontine cistern (B--D), suggesting perimesencephalic subarachnoid hemorrhage. There were mild hyperdensity lesions in right transverse sinus location (D, red arrow), suggestive of transverse sinus thrombosis.](medi-96-e7374-g001){#F1}

![The 4-vessels digital subtraction angiograms on the second day after admission showed no evidence of an intracranial aneurysm or underlying vascular malformation in vertebrobasilar artery system (A and B). Assessment of the venous phase of left internal carotid artery angiogram showed normal cortical veins, superior sagittal sinus, and left transverse sinus (D and F, green arrow). Venous phase of right internal carotid artery angiogram demonstrated prominent cerebral veins as extensive collateralizations (C and E, yellow arrow) and an absence of normal venous outflow of the right transverse sinus (C, red arrow).](medi-96-e7374-g002){#F2}

![Magnetic resonance imaging performed on the third day after admission showed an absence of flowing avoid in the area of right transverse sinus and sigmoid sinus (A--C). Axial sections of T1-weighted image (Fig. [4](#F4){ref-type="fig"}A), T2-weighted images (Fig. [4](#F4){ref-type="fig"}B), and fluid attenuated inversion recovery (FLAIR) images (Fig. [4](#F4){ref-type="fig"}C) demonstrated the presence of a hyperintense lesion on all of the 3 sequences inside the right transverse sinus, suggesting thrombosis in the right transverse sinus (A--C, yellow arrow). Axial gadolinium-enhanced T1-weighted images demonstrated filling defects in the right transverse sinus and sigmoid sinus (D, green arrow). Magnetic resonance venography demonstrated right transverse and sigmoid sinus thrombosis (E and F, red arrow).](medi-96-e7374-g003){#F3}

Routine laboratory examinations, including complete blood count, liver and renal function tests, serum electrolytes, erythrocyte sedimentation rate (ESR), and routine urine test were all within normal limits. There was not any significant abnormality in routine investigations except for an increased D-dinner level (21.7 mg/L, reference range 0.1--5 mg/L) and elevated activity of factor VIII (212%, reference range 50--150%). Regarding the etiology of the cerebral venous thrombosis, different markers of prothrombotic conditions on laboratory examinations were performed including antithrombin III, protein S, protein C, factor V Leiden, homocysteine, antiphospholipid antibodies, anti-β2-glycoprotein-1 IgM, and lupus-like anticoagulant. These results failed to provide evidence for hereditary or acquired coagulation defect. Other immune tests such as anti-nuclear antibody, anti-extractable nuclear antigen, anti-dsDNA, anti-neutrophil cytoplasmic antibodies, anti-smooth muscle antibody were all negative. Hepatitis panels and tumor biomarkers tests were all negative. Endocrinological work-up revealed hyperthyroidism on the basis of serum FT3 (14.8 pmol/L, reference range 3.60--10.82 pmol/L), serum FT4 (33.5 pmol/L, reference range 6.7--21.4 pmol/L), serum thyroid stimulating hormone (TSH) (below 0.02 mIU/L, reference range 0.9--7.10 mIU/L), antithyroglobulin antibody 1:320, and anti-TSH receptor antibody 56.5% (reference range \< 10%).

Lumbar puncture in the third day after admission demonstrated xanthochromia cerebrospinal fluid with an opening pressure of 360 mmH~2~O. Cerebrospinal fluid (CSF) test revealed 87 mg/dL of glucose, 59 mg/dL of protein, 1447 cells/mm^3^ of red blood cell and 127 cells/mm^3^ of white blood cell (52% polymorphonuclear leukocytes, 31% lymphocytes, 17% monocytes). Other inspections of CSF including gram stains, India ink stain, acid fast bacilli stain, and virological panels were all negative. Mannitol and glycerol were initiated to control the increased intracranial pressure after lumbar puncture.

The diagnosis of PNSAH caused by cerebral venous sinus thrombosis was established based on the clinical course and radiological images 3 days after admission. The diagnosis of Graves disease was established based on the results of laboratory investigations 4 days after admission. Graves disease was treated with propylthiouracil and propranolol. After informed consent was obtained on the fourth day after admission, therapy for cerebral venous thrombosis started with low-molecular weight heparin (Nadroparin, 6150AXaIU, subcutaneous injection, twice daily). Subsequent oral anticoagulant therapy with warfarin (target International normalized ratio = 2--3) was started 14 days later. The clinical symptoms were markedly improved at 10 days of posttreatment (day 14 after admission). Brain CT (Fig. [4](#F4){ref-type="fig"}A--C) on day 16 provided an apparently normal image of the perimesencephalic cistern, demonstrating a complete absorption of hemorrhage. His headache subsided on the same day with a mildly elevated CSF pressure of 200 mmH~2~O in the re-examination of lumbar puncture. The patient discharged without any neurologic defect after 3 weeks of hospital stay. At his 6-month follow-up, he had no complaints. MR venography revealed recanalization of sinus thrombosis in the corresponding area (Fig. [5](#F5){ref-type="fig"}A and B). Laboratory findings indicated normal values of free T3, free T4 level, and activity of factor VIII except for a mildly decreased TSH (0.62 mIU/L, reference range 0.9--7.10 mIU/L). Then oral anticoagulant therapy of warfarin discontinued. At his 1-year follow-up, he had no clinical relapses.

![Brain computed tomographic imaging performed on day 11 provided an apparently normal image of perimesencephalic and prepontine cisterns, demonstrating a complete absorption of hemorrhage (A, B and C, yellow arrow).](medi-96-e7374-g004){#F4}

![MR venography at 6-month follow-up revealed a recanalization of the right transverse sinus (A and B, yellow arrow).](medi-96-e7374-g005){#F5}

Timeline of clinical course, interventions and outcome shows in Figure [6](#F6){ref-type="fig"}.

![Timeline of clinical coure, interventions, and outcome.](medi-96-e7374-g006){#F6}

4. Discussion
=============

Perimesencephalic nonaneurysmal subarachnoid hemorrhage was first described as a distinct sub-type of SAH with a characteristic subarachnoid blood distribution pattern and the absence of an angiographically confirmed aneurysm.^\[[@R1],[@R3],[@R7]\]^ PNSAH was identified by computed tomographic imaging evidence of the accumulation blood around the perimesencephalic and prepontine cisterns with minimal intraventricular extension.^\[[@R3]\]^ Compared with the patients with aneurysmal SAH, patients with PNSAH typically present with a similar initial presentation of a sudden onset of an excruciating headache.^\[[@R18],[@R19]\]^ However, patients with PNSAH were associated with an excellent prognosis with an uncomplicated illness course and a low risk of rebleeding, cerebral vasospasm, hydrocephalus, delayed cerebral ischemia, no decrease in quality of life and death.^\[[@R4],[@R5],[@R7],[@R18]--[@R20]\]^ But it has been reported that cognitive impairment was common in this cohort.^\[[@R6]\]^ Several risk factors for PNSAH have been suggested such as younger age, female sex, and smoking.^\[[@R21],[@R22]\]^ Although the only risk factor consistently present in previous studies is hypertension, patients with PNSAH are more likely to have a lower frequency of hypertension than patients with aneurysm SAH.^\[[@R21],[@R22]\]^

While arterial and venous origins have already been both postulated as the source of perimesencephalic subarachnoid hemorrhage,^\[[@R7],[@R23],[@R24]\]^ the precise etiology and anatomical source of PNSAH still remain enigmatic despite recent advances in the association between venous drainage pattern of the basal vein of Rosenthal and PNSAH.^\[[@R7],[@R12]--[@R14]\]^ The most common hypothesis is that PNSAH is venous in origin due to the invariably mild initial presentation, its benign clinical course, limited extension of hemorrhage, low incidence of rebleeding and vasospasm.^\[[@R1],[@R4],[@R7]\]^ Although rupture of arterial perforators and small aneurysms has been reported sporadically,^\[[@R25],[@R26]\]^ a recent study failed to find any lesion of the basilar artery in 7 patients with PNSAH using 7-tesla vessel wall imaging technology, supporting the hypothesis that PNSAH has a venous origin.^\[[@R27]\]^ Intracranial venous hypertension has been considered as the pivotal factor in the pathogenesis of PNSAH.^\[[@R8],[@R11],[@R13],[@R14],[@R17]\]^ Elevated intracranial venous pressure can lead to vessel engorgement and venous rupture. This hypothesis is supported by reports on PNSAH induced by straining, physical exertion,^\[[@R11]\]^ performing Valsalva maneuvers, and hypoxic training during swimming.^\[[@R28]\]^ These behaviors will produce increased intrathoracic pressure and block venous flow from the brain to the right atrium, which leads to venous congestion, increased intracranial venous pressure and venous breakdown.^\[[@R11],[@R28]\]^ On the other hand, this presumption is supported by reports on more recent studies highlighting aberrant venous drainage patterns of the basal vein of Rosenthal.^\[[@R7],[@R12]--[@R14],[@R29]\]^ Van der Schaaf et al^\[[@R29]\]^ and colleagues reported that primitive drainage patterns of the basal vein of Rosenthal (BVR) directly into dural sinuses or the internal cerebral veins instead of into the Galenic venous system were much common in patients with PNSAH than those in patients with aneurysmal SAH. Furthermore, in the patients who have primitive BVR drainage in one hemisphere, hemorrhage was likely to present on the same side of the abnormal BVR drainage.^\[[@R29],[@R30]\]^ This phenomenon suggested an association between the primitive BVR drainage and PNSAH. Similar findings have been reported by different studies.^\[[@R7],[@R12],[@R14],[@R16],[@R29],[@R30]\]^ A recent meta-analysis included 8 studies investigating the prevalence of primitive BVR drainage patterns in patients with PNSAH and aneurysmal SAH.^\[[@R13]\]^ It concluded that patients with PNSAH have a higher prevalence of primitive BVR drainage than patients with aneurysmal SAH, suggested a venous origin of some PNSAH.^\[[@R13]\]^ The direct connection of the basal vein of Rosenthal with the dural sinuses may predispose to a sudden increase in intracranial venous pressure with venous engorgement and rupture as a result.

Since intracranial venous hypertension is a characteristic clinical feature of cerebral venous and sinus thrombosis, reports of associated venous rupture such as PNSAH and convexal SAH should not be surprising.^\[[@R17],[@R31]--[@R34]\]^ In our case, the occurrence of PNSAH was associated with transverse sinus thrombosis, an occurrence not yet previously reported. In our case, the venous phase of DSA demonstrated an absence of normal venous outflow of the right transverse sinus and prominent cerebral veins as extensive collateralizations. This exerted intracranial venous hypertension and retrograde hydrostatic pressure into the cerebral deep veins system which bridge the perimesencephalic and prepontine subarachnoid space that resulted in a rupture of perimesencephalic veins.^\[[@R17],[@R34]\]^ The veins in the corresponding anatomic location have relatively thin vessel walls without smooth muscle fibers and venous valves, also contributing to the rupture of venous.

Our case of PNSAH strengthens the evidence linking PNSAH with venous hypertension associated with underlying venous pathology in the cerebral venous circulation. We searched for case reports of venous abnormalities associated with PNSAH by conducting a search of PubMed. Table [1](#T1){ref-type="table"} showed the results: 11 patients with underlying venous pathology associated with PNSAH. Venous abnormalities, including venous aneurysm,^\[[@R35]\]^ venulitis associated with Behcet disease,^\[[@R17]\]^ stenosis or occlusion of vein of Galen, straight sinus, jugular vein and brachiocephalic vein, and cerebral venous thrombosis of cavernous sinus,^\[[@R34]\]^ widespread sinuses,^\[[@R17]\]^ straight sinus, and the vein of Galen,^\[[@R17]\]^ have been implicated in various case reports as potential sources of the bleeding. So, underlying venous pathology may be identified as an important predisposing factor in the pathogenesis of PNSAH. Most of the cases with PNSAH caused by underlying venous pathology had an excellent outcome without any complication.^\[[@R8],[@R9],[@R15],[@R17],[@R35]\]^ However, patients with cerebral venous thrombosis were likely to have poorer neurological symptoms, higher scores of WFNS scale, longer duration of hospital stay together with higher frequencies of initial neurologic deficits, poor outcome relevant complication including rebleeding and hemorrhagic infarction.^\[[@R17],[@R34]\]^ The prognosis of patients with PNSAH caused by CVST is not as good as those of patients with PNSAH caused by other etiology. Although the prognosis of CVST is usually favorable and the mortality is relatively low, the functional outcome and mortality may vary in different condition. Data from the largest CVST registry of the National Inpatient Sample revealed that intracranial hemorrhage (ICH) was an independent predictor of increased risk of mortality (adjusted OR = 5.4, 95% CI = 4.38--7.96).^\[[@R36]\]^ Motor deficits and ICH were also strongly associated with poor outcome in the International Study on Cerebral Vein and Dural Sinus Thrombosis study (ISCVT) cohort and a Pakistani series.^\[[@R37]\]^ In the ICH subgroup analysis of ISCVT cohort study, patients were older, and more likely to have severe clinical presentations and a much worse 6-month prognosis than those in CVST patients without ICH. Having a thrombosis in the deep cerebral venous system (adjusted odds ratio \[adjusted OR\] = 5.43; 95% confidence interval \[95% CI\] = 1.67--17.61), or a right transverse sinus thrombosis (adjusted OR = 2.56; 95% CI = 1.03--6.40), and having a motor deficit (adjusted OR = 2.94; 95% CI = 1.21--7.10) were the key predictors of poor prognosis.^\[[@R38]\]^ Since SAH and deep cerebral venous system involved were the characteristic clinical features of PNSAH, poor prognosis in patients with PNSAH caused by CVST should not be surprising. On the other hand, patients complicated with CVST might have acute and progressive intracranial venous hypertension compared with patients with PNSAH caused by other etiology, this might contribute to the development of poor outcome. So, early evaluation of CVST is very important for the treatment of PNSAH. In addition to the evidence from digital subtraction venography, there are some case reports that reveal intracranial venous hypertension associated with spinal arteriovenous fistula and thoracolumbar spinal vascular malformation,^\[[@R39]\]^ may lead to PNSAH. We suggest a comprehensive analysis of cerebral veins must be performed in patients with PNSAH to determine whether there is an underlying venous pathology or a primitive BVR drainage pattern.

###### 

Cases of perimesencephalic nonaneurysmal subarachnoid hemorrhage caused by underlying venous pathology.

![](medi-96-e7374-g007)

In this case, there was no significant abnormality in coagulative investigations except for an increased D-dinner level and elevated activity of factor VIII. Connective tissue disease, antiphospholipid syndrome, deficiencies of antithrombin, protein C or protein S, or factor V Leiden were excluded by the relevant laboratory examination. CVST has been reported as a cerebrovascular complication of hyperthyroidism in a number of previous studies.^\[[@R40]--[@R42]\]^ Hyperthyroidism may be a predisposing factor for CVST in our case through a hypercoagulable state including increase in acute-phase reactants, elevated activity of thrombin and fibrinogen, and decrease in fibrinolytic activity.^\[[@R40]--[@R42]\]^ But the available literature does not provide an answer to the need for prolonged anticoagulant therapy in patients with CVST and hyperthyroidism, we discounted anticoagulant therapy at 6-month follow-up according to the available guidelines.

The management of CVST with subarachnoid hemorrhage is controversial and not well established. The most recent guidelines proposed by the AHA for CVST state that once the diagnosis of CVST has been confirmed, anticoagulation treatment should be initiated immediately even in the setting of intracerebral hemorrhage.^\[[@R43]\]^ The recommendation for patients with CVST and intracerebral hemorrhage is based on the assumption that the treatment of anticoagulation can prevent thrombus formation and promote spontaneous recanalization of the existing thrombus more than it promotes the development of bleeding.^\[[@R44]\]^ However, there is only rare evidence on the benefit and bleeding risk of systemic anticoagulation in patients with SAH and PNASH induced by CVST.^\[[@R17],[@R31]--[@R33],[@R43]\]^ On the base of pathological assumption of PNSAH, anticoagulation is likely to be effective without extension of bleeding in the current case combined with these previous reports. However, the optimal anticoagulation dosing, initiation time of anticoagulation, and monitoring tests for anticoagulation have not been well established.^\[[@R43],[@R45],[@R46]\]^ For patients with CVST and SAH, intracranial aneurysm must be ruled out before anticoagulation by using magnetic resonance angiography or digital subtraction angiography. Meanwhile, repeating CT after at least 1 day from onset of symptoms is recommended to confirm that hemorrhage is reducing or at least not progressing before starting anticoagulation.^\[[@R46]\]^ Initial anticoagulation is generally with adjusted-dose unfractionated heparin (UFH) or weight-based low molecular weight heparin (LMWH) in full anticoagulant doses.^\[[@R40]\]^ Recent studies demonstrated LMWH had better efficacy and safety in comparison with UFH, with lower risk of major hemorrhage, thrombotic complications, and death.^\[[@R47]\]^ As the pharmacokinetic parameter of LMWH is well defined for normal weight patients, monitoring is not required as a routine test for LMWH according to the American college of chest physicians (ACCP) and British society for haematology guidelines.^\[[@R48]\]^ In some special condition such as obese patients, pregnant patients, patients with renal impairment, and patients with high risk of hemorrhage, anti-Xa activity assay may be of some value in the investigation of pharmacokinetics of LMWH.^\[[@R48],[@R49]\]^ However, anti-Xa activity assay seems to have poor predictive value for risk of hemorrhage and antithrombotic efficacy.^\[[@R48],[@R49]\]^ Other parameters, including thrombin generation assay, platelet contractile force, clot elastic modulus, and thromboelastography, have been applied to monitor pharmacokinetics of LMWH, but still lack of evidence.^\[[@R49]\]^ The treating dosage of LMWH for patients with increased bleeding risk suggested by Babin et al^\[[@R49]\]^ is 86 units/kg twice daily with a recommended therapeutic anti-Xa level from 0.5 to 1.1 U/mL. In clinical practice, repeat CT scan when necessary, platelet count detection together with the careful clinical observation of conscious state, neurologic impairment, skin or mucous hemorrhage, symptoms and signs of intracranial hypertension were the method to monitor the drug effect of anticoagulants.

5. Conclusion
=============

The present case is the first to describe the occurrence of transverse sinus thrombosis in relation to PNSAH. Hyperthyroidism related to Graves disease may contribute to the development of CVST. The pathophysiologic mechanism of PNSAH in our case could provide further support to the hypothesis that the source of PNSAH is venous in origin and intracranial venous hypertension may play a key role in the pathogenesis of PNSAH. Our case combined with the underlying venous pathology of PNSAH from recent reports provides a better understanding the pathogenesis and management of PNSAH. Comprehensive analysis of cerebral veins may help to establish the cause of PNSAH.

Abbreviations: AHA = American Heart Association, BVR = basal vein of rosenthal, CSF = cerebrospinal fluid, CT = computed tomography, CTA = computed tomography angiography, CVST = cerebral venous sinus thrombosis, DSA = digital subtraction angiography, FT3 = free triiodothyronine, FT4 = free thyroxine, MRI = magnetic resonance imaging, PNSAH = perimesencephalic nonaneurysmal subarachnoid hemorrhage, SAH = subarachnoid hemorrhage, TSH = thyroid stimulating hormone, WFNS = World Federation of Neurological Surgeons.
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